Sort by
Neuroscience
4 Aminobutyric Acid B Receptor
14%
Alprazolam
9%
Anticonvulsant
14%
Baclofen
18%
Behavior (Neuroscience)
11%
Cortical Excitability
15%
Diazepam
15%
Droxidopa
11%
Electroencephalogram
7%
Electromyography
11%
Electromyography
5%
Evoked Potential
35%
Excitability
5%
Face
35%
GABAA Receptor
12%
Inhibition-Excitation Balance
5%
Lamotrigine
11%
Levetiracetam
11%
Motor Cortex
23%
Motor Evoked Potential
15%
Neural Oscillation
11%
Occipital Lobe
11%
Parkinson's Disease
11%
Placebo
14%
Primary Motor Cortex
18%
Receptor Agonists
7%
Synaptic Transmission
27%
Transcranial Direct Current Stimulation
11%
Transcranial Magnetic Stimulation
100%
Zolpidem
6%
Pharmacology, Toxicology and Pharmaceutical Science
4 Aminobutyric Acid
11%
4 Aminobutyric Acid B Receptor
5%
4 Aminobutyric Acid B Receptor Stimulating Agent
5%
Alprazolam
11%
AMPA Receptor
5%
AMPA Receptor Antagonist
5%
Anticonvulsive Agent
28%
Baclofen
11%
Benzodiazepine
11%
Biological Marker
15%
Clinical Trial
13%
Dextromethorphan
11%
Diazepam
11%
Droxidopa
11%
EEG Abnormality
5%
Lamictal
29%
Levetiracetam
29%
N Methyl Dextro Aspartic Acid Receptor
5%
N Methyl Dextro Aspartic Acid Receptor Blocking Agent
5%
Nimodipine
11%
Normal Human
23%
Orthostatic Hypotension
11%
Parkinson's Disease
11%
Perampanel
11%
Pharmacodynamics
11%
Placebo
32%
Positive Allosteric Modulator
5%
Potassium Channel Stimulating Agent
5%
Receptor
11%
Voltage-Gated Calcium Channel Blocker
5%
Zolpidem
11%
Medicine and Dentistry
4 Aminobutyric Acid B Receptor
5%
Anticonvulsant
11%
Antipsychotic
11%
Biological Marker
12%
Biometry
11%
Cerebral Cortex
5%
Clozapine
5%
Disease Exacerbation
5%
Diseases
11%
Droxidopa
11%
Electromyography
5%
Functional Connectivity
5%
Gamma-Aminobutyric Acid
11%
Glutamic Acid
5%
Interneuron
5%
Lamotrigine
11%
Levetiracetam
11%
Mental Health
11%
National Health Service
11%
Nerve Cell Inhibition
5%
Orthostatic Hypotension
11%
Parkinson's Disease
23%
Pharmacodynamics
11%
Physiological Process
5%
Schizoaffective Disorder
5%
Systematic Review
11%
Therapy Effect
5%
Transcranial Magnetic Stimulation
26%
Treatment-Resistant Schizophrenia
5%
Wearable Sensor
11%